**Supplementary table 1.** Primary and secondary outcomes of patients with intracerebral hematoma and ischemic stroke receiving amlodipine and metoprolol.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Outcome** | **Intracerebral hemorrhage**  (n = 83) | | | **Ischemic stroke**  (n = 42) | | |
| Primary outcome | Amlodipine  (n = 45) | Metoprolol (n = 38) | p-value | Amlodipine  (n = 18) | Metoprolol (n = 24) | p-value |
| Death at 1 month | 9(20%) | 4(10.5%) | 0.24 | 3(16.7%) | 2(8.3%) | 0.64 |
| Secondary outcome |  |  |  |  |  |  |
| Pneumonia  Sepsis  SIRS at 7th day  SIRS at 15th day  GIH  3-months outcome    Good  Poor | 11(24.4%)  5(11.1%)  27(64.3%)  15(33.3%)  8(17.8%)  14(31.1%)  22(48.9%) | 9(23.7%)  4(10.5%)  26(70.3%)  11(28.9%)  5(13.2%)  27(71.1%)  7(18.4%) | 0.94  1.00  0.57  0.42  0.56  < 0.05 | 5(27.8%)  1(5.6%)  8(44.4%)  4(22.2%)  2(11.8%)  7(38.9%)  8(44.4%) | 75(29.2%)  0(0%)  14(58.3%)  8(33.3%)  5(20.8%)  18(75%)  4(16.7%) | 0.92  0.43  0.50  0.51  0.68  0.06 |

GIH: gastrointestinal bleeding, SIRS: Systemic Inflammatory respiratory syndrome,

**Supplementary table 2**. Predictors of death at one month on univariate analysis

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **Survived**  [n=107 (85.6%)] | **Death**  [n=18 (14.4%)] | **p-value** |
| Age in years | 61.69 ± 12.193 | 60.72 ± 12.69 | 0.76 |
| Females | 39(36.4%) | 8(44.4%) | 0.60 |
| Hypertension | 93 (87.0%) | 16(88.9%) | 0.65 |
| Diabetes | 31(28.9%) | 2(11.1%) | 0.15 |
| Cardiac disease  None  Present  CAD  RHD  NVAF | 77(72%)  30(28%)  25(23.4%)  1(0.9%)  4(3.7%) | 10(55.6%)  8(44.4%)  2(11.1%)  2(11.1%)  4(22.2%) | 0.17 |
| Seizure | 16(15%) | 5(27.8%) | 0.30 |
| GCS score at admission | 12.02 ± 2.67 | 7.56 ± 3.11 | < 0.001 |
| NIHSS score at admission | 15.81 ± 6.80 | 25.0 ± .481 | < 0.001 |
| SIRS at admission | 75(70.1%) | 17(94.4%) | 0.04 |
| Stroke type  Ischemic  Hemorrhagic | 37(34.6%)  70(65.4%) | 5(27.8%)  13(72.2%) | 0.61 |
| Size of stroke  Small  Medium  Large | 38(35.5%)  46(43%)  23(21.5%) | 3(16.7%)  3(16.7%)  12(66.7%) | < 0.001 |
| Midline shift in cm | 0.39 ± 0.42 | 0.94 ± 0.73 | 0.02 |
| Raised Trop I | 37(34.6%) | 11(61.1%) | 0.04 |

CAD: coronary artery disease, GCS: Glasgow Coma Scale, RHD: rheumatic heart disease, NVAF: non-valvular atrial fibrillation, SIRS: Systemic Inflammatory respiratory syndrome, NIHSS: National Institute of Health stroke scale.

**Supplementary table 3.** Predictors of good outcome at 3 months

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **Good**  (n = 66) | **Poor**  (n = 41) | **p-value** |
| Age in years | 61.36 ± 12.67 | 62.22 ± 11.50 | 0.73 |
| Female | 24(36.4%) | 15(36.6%) | 1.00 |
| Hypertension | 57(86.4%) | 36(87.8%) | 1.00 |
| Diabetes | 21(31.8%) | 10(24.4%) | 0.51 |
| Cardiac disease  None  Present  CAD  RHD  NVAF | 45(68.2%)  21(31.8%)  17(25.8%)  1(1.5%)  3(4.5%) | 32(78%)  9(22%)  8(19.5%)  0(0%)  1(2.4%) | 0.38 |
| Seizure | 11(16.7%) | 5(11.2%) | 0.59 |
| GCS score at admission | 12.17±2.55 | 11.78±2.87 | 0.47 |
| NIHSS score at admission | 15.08±7.0 | 17.0 ±6.37 | 0.16 |
| SIRS at admission | 45(68.2%) | 30(73.2%) | 0.67 |
| SIRS at 7th day | 33(50%) | 30(75%) | 0.01 |
| SIRS at 15th day | 10(15.4%) | 20(66.7%) | < 0.001 |
| Stroke type  Ischemic  Intracerebral hemorrhagic | 25(37.9%)  41(62.1%) | 12(29.3%)  29(70.7%) | 0.41 |
| Size of stroke  Small  Medium  Large | 10(15.2%)  30(45.5%)  26(39.4%) | 13(31.7%)  16(39%)  12(29.3%) | 0.12 |
| Midline shift in cm | 0.27 ± 0.39 | 0.44 ± 0.46 | 0.046 |
| Raised Torp I | 21(31.8%) | 16(39%) | 0.53 |
| Metoprolol | 47(75.8%) | 15(24.2%) | 0.002 |

CAD: coronary artery disease, GCS: Glasgow Coma Scale, RHD: rheumatic heart disease, NVAF: non-valvular atrial fibrillation, SIRS: Systemic Inflammatory respiratory syndrome, NIHSS: National Institute of Health stroke scale.